The therapeutic potential of the proteasome in leukaemia (Q37103852)

18 August 2017

1 reference

title

The therapeutic potential of the proteasome in leukaemia (English)

1 reference

18 August 2017

1 reference

Scott Marshall McCloskey

1

1 reference

18 August 2017

Mary Frances McMullin

2

1 reference

18 August 2017

Brian Walker

3

1 reference

18 August 2017

Alexandra E Irvine

4

1 reference

18 August 2017

language of work or name

1 reference

1 June 2008

1 reference

18 August 2017

Hematological Oncology

1 reference

18 August 2017

26

1 reference

18 August 2017

2

1 reference

18 August 2017

73-81

1 reference

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

18 August 2017

1 reference

Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol

21 January 2018

1 reference

Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins.

21 January 2018

1 reference

The ubiquitin-proteasome pathway in cell cycle control.

21 January 2018

1 reference

7 January 2021

Ubiquitin: Roles in protein modification and breakdown

1 reference

7 January 2021

Nucleotide excision repair and the ubiquitin proteasome pathway--do all roads lead to Rome?

1 reference

7 January 2021

Regulation of ROMK (Kir1.1) channels: new mechanisms and aspects

1 reference

7 January 2021

E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation

1 reference

7 January 2021

Mechanism and function of deubiquitinating enzymes

1 reference

7 January 2021

Proteasomes: machines for all reasons

1 reference

7 January 2021

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

1 reference

7 January 2021

Proteasomes and their kin: proteases in the machine age

1 reference

7 January 2021

1 reference

7 January 2021

Structure and functions of the 20S and 26S proteasomes

1 reference

7 January 2021

Subtypes of 20S proteasomes from skeletal muscle

1 reference

7 January 2021

Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing

1 reference

7 January 2021

Global organization and function of mammalian cytosolic proteasome pools: Implications for PA28 and 19S regulatory complexes

1 reference

7 January 2021

The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides.

1 reference

7 January 2021

Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition

1 reference

7 January 2021

Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity.

1 reference

7 January 2021

Phosphorylation of proteasomes in mammalian cells. Identification of two phosphorylated subunits and the effect of phosphorylation on activity

1 reference

7 January 2021

N(alpha)-acetylation and proteolytic activity of the yeast 20 S proteasome

1 reference

7 January 2021

Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon

1 reference

7 January 2021

26S proteasome subunits are O-linked N-acetylglucosamine-modified in Drosophila melanogaster

1 reference

7 January 2021

Proteasome plasticity.

1 reference

7 January 2021

Comprehensive quantitative proteome analysis of 20S proteasome subtypes from rat liver by isotope coded affinity tag and 2-D gel-based approaches

1 reference

7 January 2021

Protein degradation by the ubiquitin-proteasome pathway in normal and disease states

1 reference

7 January 2021

Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity

1 reference

7 January 2021

Aging and the ubiquitinome: traditional and non-traditional functions of ubiquitin in aging cells and tissues.

1 reference

7 January 2021

MYC degradation: deubiquitinating enzymes enter the dance

1 reference

7 January 2021

Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1

1 reference

7 January 2021

A ubiquitin stress response induces altered proteasome composition.

1 reference

7 January 2021

Inactivation of the proteasome by 4-hydroxy-2-nonenal is site specific and dependant on 20S proteasome subtypes

1 reference

7 January 2021

Alteration of 20S proteasome-subtypes and proteasome activator PA28 in skeletal muscle of rat after induction of diabetes mellitus

1 reference

7 January 2021

Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome."

1 reference

7 January 2021

Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors

1 reference

7 January 2021

Proteasome activator PA200 is required for normal spermatogenesis

1 reference

7 January 2021

PI31 is a modulator of proteasome formation and antigen processing

1 reference

7 January 2021

Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity

1 reference

7 January 2021

Impaired proteasome function in Alzheimer's disease

1 reference

7 January 2021

Amyloid peptide attenuates the proteasome activity in neuronal cells

1 reference

7 January 2021

Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease

1 reference

7 January 2021

Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.

1 reference

7 January 2021

The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity.

1 reference

7 January 2021

Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion

1 reference

7 January 2021

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

1 reference

7 January 2021

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl

1 reference

7 January 2021

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism

1 reference

7 January 2021

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

1 reference

7 January 2021

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex

1 reference

7 January 2021

NMDA antagonists exacerbate neuronal death caused by proteasome inhibition in cultured cortical and striatal neurons

1 reference

7 January 2021

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

1 reference

7 January 2021

Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals)

1 reference

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

7 January 2021

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

7 January 2021

A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma

1 reference

7 January 2021

Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma

1 reference

7 January 2021

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

7 January 2021

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

1 reference

7 January 2021

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

7 January 2021

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

1 reference

7 January 2021

Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.

1 reference

7 January 2021

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

7 January 2021

Abnormally high expression of proteasomes in human leukemic cells

1 reference

7 January 2021

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

1 reference

7 January 2021

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

1 reference

7 January 2021

M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis

1 reference

7 January 2021

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

1 reference

7 January 2021

Proteasome inhibition in hematologic malignancies

1 reference

7 January 2021

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

7 January 2021

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

1 reference

7 January 2021

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

7 January 2021

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

7 January 2021

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

7 January 2021

Chronic myeloid leukemia – some topical issues

1 reference

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

7 January 2021

Punish the parent not the progeny.

1 reference

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

7 January 2021

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

1 reference

7 January 2021

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

1 reference

7 January 2021

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

1 reference

7 January 2021

Therapeutic targets in chronic myeloid leukaemia

1 reference

7 January 2021

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

1 reference

7 January 2021

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta

1 reference

7 January 2021

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

1 reference

7 January 2021

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

1 reference

7 January 2021

Clinical update: proteasome inhibitors in solid tumors

1 reference

7 January 2021

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

1 reference

7 January 2021

Targeting NF-kappaB in hematologic malignancies

1 reference

7 January 2021

The ubiquitin-proteasome pathway and its role in cancer

1 reference

7 January 2021

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

7 January 2021

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.848

1 reference

18 August 2017

1 reference